Showing 1341 - 1350 of 1366 for "ITC litigation" with applied filters
Filters:
01 September 2018 by ABE & Partners
The Japanese IP system has vulnerable evidence collection procedures in comparison with foreign countries.
01 September 2018 by Managing Intellectual Property
Early this year, the Mexican Institute of Industrial Property issued decisions denying registration for the trade mark PINCHE GRINGO BBQ & Design in classes 43 (restaurants) and 30 (sauces)
01 September 2018 by Norton Rose Fulbright
Big names in Hollywood, sports, and music often enforce their personality rights
02 July 2018 by Takanori Abe
Shionogi is the owner of a patent entitled Pyrimidine Derivatives (JP2648897). X filed a request for a trial for invalidation of the patent. Nippon Chemiphar intervened in the trial as a plaintiff, and AstraZeneca UK intervened in the trial in order to support the defendant.
02 July 2018 by Karen Artz Ash
Although it is the general policy of the USPTO’s Trademark Trial and Appeal Board (TTAB) to suspend opposition proceedings when the parties to such proceedings become involved in a civil action which may be dispositive of the case, a recent decision issued by the US District Court for the District of Delaware in Tigercat Int’l, Inc. v Caterpillar Inc. indicates that there are circumstances where, conversely, federal courts will stay a litigation pending a TTAB ruling.
02 July 2018 by Sybille Pfender
At the end of April 2018, Advocate General (AG) Wathelet handed down an advisory opinion regarding the first of three recent referrals to the CJEU (C-121/17). This concerns the interpretation of Article 3(a) of Regulation (EC) No 469/2009.
01 June 2018 by Managing Intellectual Property
The Intellectual Property Enterprise Court (IPEC) has an objective to provide quick and cost-effective IP litigation. It has proved to be popular.
01 June 2018 by Karen Artz Ash
The US Supreme Court’s ruling in B&B Hardware, Inc v Hargis Industries, Inc provided that courts were obligated to give preclusive effect to decisions made by the US Patent and Trademark Office’s Trademark Trial and Appeal Board (TTAB) if the ordinary elements of issue preclusion are met
01 June 2018 by Henri van Kalkeren
Cialis® is a pharmaceutical product for the treatment of erectile dysfunction developed by Lilly ICOS, a joint venture of ICOS Corporation and Eli Lilly and Company.
01 June 2018 by Klaus Breitenstein
In recent ex-parte appeal proceedings (decision 14 W (pat) 10/16 of January 23 2018), the German Federal Patent Court (GFPC) contributed to the interpretation of Article 3(a) of Regulation (EC) No 469/2009 (the Regulation).
